User:Mr. Ibrahem/Daunorubicin/cytarabine

Daunorubicin/cytarabine is a combination medicine used to treat acute myeloid leukemia (AML). Specifically it is used for therapy related disease (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It is given by a central venous line. The combination differs from the individual components.

Common side effects include bleeding, low neutrophils, rash, swelling, nausea, diarrhea, tiredness, cough, arrhythmias, and sepsis. Other side effects may include heart toxicity, anaphylaxis, and tissue necrosis. Use in pregnancy may harm the baby. Daunorubicin is an anthracycline topoisomerase inhibitor while cytarabine is a nucleoside metabolic inhibitor. These are contained with liposomes.

The combination was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom a vial of 44 mg daunorubicin/100 mg cytarabine costs the NHS about £4,600 as of 2021. This amount in the United States costs about 9,300 USD.